Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x100px

Product › Details

thiazolidinedione

	Next higher product group	antidiabetic
	Status	1997-10-01 sales start
	Status	2002-11-01 sales existent
	Organisation	Glaxo Wellcome (Group)
	Today	GSK (Group)
	Group	GSK (Group)

Record changed: 2023-07-10

Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x200px

More documents for antidiabetic

[1] ProBioGen AG. (1/6/26). "Press Release: ProBioGen and Zag Bio Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy". Berlin....
[2] Pfizer Inc.. (11/13/25). "Press Release: Pfizer Completes Acquisition of Metsera". New York, NY....
[3] Zag Bio, Inc.. (10/28/25). "Press Release: Zag Bio Launches with $80 Million Financing to Advance Thymus-targeted Medicines for Autoimmune Diseases". Cambridge, MA....
[4] Pfizer Inc.. (9/22/25). "Press Release: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio". New York, NY....
[5] Boehringer Ingelheim. (7/24/25). "Press Release: First Half of 2025 – Solid Growth, Investments and Pipeline Progress Pave the Way for Two Key Launches in H2". Ingelheim....
[6] Boehringer Ingelheim. (4/2/25). "Press Release: Boehringer Ingelheim Reaches more Patients in 2024 and Prepares New Medicine Launches". Ingelheim....
[7] Roche. (3/12/25). "Press Release: Roche Enters into an Exclusive Collaboration & Licensing Agreement with Zealand Pharma to Co-develop and Co-commercialise Petrelintide as a Potential Foundational Therapy for People with Overweight and Obesity". Basel....
[8] Zealand Pharma A/S. (3/12/25). "Press Release: Zealand Pharma and Roche Enter Collaboration and License Agreement to Co-develop and Co-commercialize Petrelintide as a Future Foundational Therapy for People with Overweight and Obesity". Copenhagen....
[9] Hangzhou Sciwind Biosciences Co., Ltd.. (1/10/25). "Press Release: Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio". Hangzhou....
[10] Verdiva Bio Ltd.. (1/9/25). "Press Release: Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies". London & San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]